[Newsmp] In the first quarter, major pharmaceutical companies’ sales related to cold medicine and antipyretics increased significantly.
Since February, demand for cold medicines and antipyretics has risen remarkably due to the expansion of at-home treatment after the spread of the COVID-19 Omicron variant.
Accordingly, Newsmp compiled the reports of major pharmaceutical companies that indicated sales of cold medicines and antipyretics in the first quarter and found that all of them had a strong performance.
In particular, some companies newly included sales of cold medicines and antipyretics that were not counted last year.
The counting method differs from company to company, so some companies reported by grouping them as comprehensive cold medicine or antipyretics, and some companies counted them as individual drugs.
By drug, Daewon Pharmaceutical’s Codaewon Forte stood out the most.
Codaewon Forte, which generated KRW 3.5 billion in sales in the first quarter of last year, expanded its sales to KRW 13.4 billion year-on-year, recording a growth rate of 285.5%. This figure is close to KRW 16.5 billion in annual sales last year.
Dong Wha Pharm’s Pan Cold preparations also grew 27.2% and jumped from KRW 8.7 billion to KRW 11.1 billion, while Kwang Dong Pharmaceutical’s Ssanghwatang preparations rose 83.7% from KRW 2.6 billion to KRW 4.9 billion.
Yuhan Corporation’s Cough-S Syrup and Bukwang Pharmaceutical’s Tacenol, which did not include sales in last year’s report, posted sales of KRW 7.9 billion and KRW 2.5 billion.
As for the product line, sales of Korean Drug’s comprehensive cold medicine jumped 654.1% from KRW 122 million to KRW 920 million, the largest increase.
In addition to the comprehensive cold medicine, Korean Drug reported sales of KRW 200 million of antipyretics and analgesics, which were not counted last year.
Sam-A Pharmaceutical’s antipyretics, analgesics, and anti-inflammatory drug sales also surged 227.3% from KRW 983 million to KRW 3.217 billion.
Moreover, Ahn-Gook Pharmaceutical‘s antipyretics and analgesics increased by 63.7% from KRW 945 million to KRW 1.547 billion, Reyon Pharmaceutical’s anti-inflammatory drugs by 32.6% from KRW 1.969 to KRW 2.611 billion, and Whanin Pharmaceutical’s antipyretics, analgesics, and anti-inflammatory drugs by 6.4% from KRW 1.167 billion to KRW 1.242 billion.
